The Four Psychedelics ETFs Capturing Investor Attention

The Four Psychedelics ETFs Capturing Investor Attention

Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success will vary.

Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis

Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.
Compass Pathways Psilocybin Patent Upheld

Compass Pathways Psilocybin Patent Upheld

Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.

Numinus Acquiring Novamind in First Major Psychedelics Merger

This deal will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.

Latest News

Treating Stress with Wearable Technology

Can Wearable Technology Help Alleviate Stress?

, ,
Can wearable technology help alleviate stress? Apollo Neuro's new wearable shows amazing promise
Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

, ,
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Compass Pathways Psilocybin Patent Upheld

Compass Pathways Psilocybin Patent Upheld

,
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.

Cybin Acquires Entheon’s DMT Trial, Numi’s Novamind Acq. Complete, Bad News for MindMed and More

This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and...
Psychedelic Business Spotlight - June 17

Psychedelic Business Spotlight – June 17

, ,
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
The Four Psychedelics ETFs Capturing Investor Attention

The Four Psychedelics ETFs Capturing Investor Attention

,
Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success...

Psychedelic Business Spotlight – June 10

,
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and...

Psychedelic Business Spotlight – June 3

,
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind files for a new patent; and much more!

Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview

In today's episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA. ATMA is a company that is primarily focused on training therapists on how...





Does MDMA Reduce Fear?

Does MDMA Reduce Fear? New Study Has Implications for PTSD Treatment

Using a measurement tool called the SCR, researchers found that combining MDMA with fear extinction learning and recall therapy significantly reduced the fear felt by study participants, as compared to the placebo. This may have big implications for how we treat PTSD.